Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
The company is also counting on newer medicines to lessen its dependence on aging blockbuster drugs
Pfizer has said it expects to return to stronger growth after 2028
August 04, 2026 15:32
GENEVA: Pfizer on Tuesday reported better-than-expected second-quarter results, boosted by strong demand for blood thinner Eliquis, and unveiled plans for an additional $2.5 billion in savings through its ongoing cost-cutting efforts.
